Search

everythinglearnresearchcommunity

for

Search:↓

This conversation is about a user's post showing their progress in hair growth after four months of taking finasteride and minoxidil, although it was later revealed that they had also received a hair transplant. The replies to the post were mixed, with some questioning the validity of the results and others expressing admiration.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A male in his late 20s, with Norwood 7 hair loss, reports progress using topical 5% minoxidil twice daily, natural hair regrowth oils, and derma rolling. He plans to start finasteride or dutasteride after noticing positive results.

A female in her late 30s experienced hair thinning due to health issues and treatments, including antibiotics and stress. She started using minoxidil, biotin, and vitamins from **hers** and is currently dealing with shedding and possible weight gain.

A user in their late thirties is skeptical about the effectiveness of a hair growth supplement and is considering switching to cheaper alternatives like Biotin. They currently use finasteride, microneedling, and are contemplating switching to Dutasteride and purchasing Nizoral shampoo.

The user experienced aggressive hair thinning starting in late 2023 and began using Minoxidil consistently in October 2025, along with Vitamin D supplements. After three months, they shared progress photos showing improvement in hair density.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

The user has been using finasteride since late 2021 and added oral minoxidil in mid-2024, considering adding dutasteride for better results. Users discuss the effectiveness and side effects of these treatments, with some recommending ketoconazole shampoo for redness.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

The user has been using 5% minoxidil and 1mg finasteride since late 2024 and has seen progress in hair regrowth, though they feel it is slowing down. They are considering adding rosemary oil and derma stamping to their routine, with advice suggesting derma stamping once a week at 1mm to 1.5mm.

The user has been using liposomal topical finasteride since late 2022, progressively increasing the dose, but DHT serum levels remain largely unchanged. Despite using finasteride, minoxidil, microneedling, and ketoconazole, hair condition has neither improved nor worsened.

The user has been using Minoxidil and Finasteride since late 2019 with good results but is experiencing a dry, flaky scalp and shedding hairs. They also use Nizoral, biotin, zinc, magnesium, and collagen supplements, and their dermatologist prescribed fluocinolone acetonide to reduce flaking.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

The user has been using oral finasteride 1mg and oral minoxidil 2.5mg daily since late 2024 and reports positive progress in hair growth without side effects, though some unwanted hair growth on hands and arms. The user is 26 years old and started losing hair around age 20 or 21.

A user is disappointed with their 6-month hair loss treatment progress, using 1.25mg oral finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil, derma stamping, vitamin D, caffeine, benzoyl peroxide wash, and tretinoin. Replies suggest the results are good, especially considering the late start of treatment, and encourage continued use for better outcomes.

A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

A 29-year-old male with diffuse thinning plans to start minoxidil and finasteride soon but is concerned about potential shedding before a big event in late April/early May. He is considering whether to start treatment now or wait until after the event.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The user started using minoxidil on May 1, 2025, and finasteride in late May 2025, along with dermarolling, saw palmetto, biotin, and a natural shampoo for hair loss treatment. They report satisfaction with progress and emphasize consistency in their regimen.

The user experienced significant hair regrowth in three months using a capsule containing minoxidil and finasteride. They reported no major side effects and plan to continue the treatment until their late 20s.

A 36-year-old considering a fourth hair transplant is advised to either shave his head or use a hair system due to poor results from previous transplants and late medication use. He plans to consult top surgeons and adjust his current treatments, including finasteride and minoxidil.

The conversation discusses various celebrities who reportedly use hair loss treatments like finasteride and dutasteride. Users share their experiences and opinions on starting treatment, with some encouraging the original poster to consult a dermatologist and consider treatment before it's too late.

The user shared a 9+ month hair loss treatment progress with 1mg finasteride in the morning, 2.5mg oral minoxidil at night, and vitamin A spray at night, noting the importance of seeing a dermatologist early as their cousin started treatment too late for it to be effective.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.